Can acupuncture help tame ulcerative colitis?
NCT ID NCT07389824
First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 2 times
Summary
This study tests whether adding acupuncture to the standard drug mesalazine helps people with mild-to-moderate ulcerative colitis achieve and stay in remission. Eighty adults will receive either real acupuncture or sham patches alongside mesalazine for 12 weeks. The goal is to see if the combination improves symptoms like bleeding and stool frequency better than the drug alone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Acupuncture (intradermal thumbtack needles) and mesalazine
- What this could lead to
- If it works, this could point toward a drug-free add-on therapy to better control ulcerative colitis symptoms and maintain remission.
- What could go wrong
- This is a small, early-stage trial at a single center. The sham acupuncture control may not fully rule out placebo effects, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 66 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. documented diagnosis of UC; 2. age 18-75 years, regardless of gender; 3. mildly to moderately active UC, defined as a baseline total Mayo score between 3 and 10; 4. willing to receive the complete protocol of intradermal thumbtack needle embedding therapy (12 sessions across three treatment courses); 5. Willing to undergo two colonoscopies (pre-treatment and post-treatment); 6. complete all baseline assessments; 7. capable of understanding and voluntarily sign the informed consent form. Exclusion Criteria: 1. diagnosed with or suspected to have other type of inflammatory bowel disease, such as Crohn's disease; 2. patients in clinical remission or with severe disease activity ( baseline total Mayo score \< 3, or \> 10 ); 3. having severe gastrointestinal complications or a recent surgical history, including but not limited to: short bowel syndrome, toxic megacolon, intestinal perforation, complete intestinal obstruction, active massive gastrointestinal hemorrhage, or having undergone major abdominal or intestinal surgery within the past 6 months. 4. patients unwilling to undergo colonoscopy; 5. significant or unstable comorbidities (e.g., cardiovascular, respiratory, hepatic, or renal diseases); 6. patients with malignant tumors (including but not limited to colorectal cancer); 7. patients with a history of intradermal thumbtack needle embedding; 8. pregnant or lactating women; 9. patients with mental illness; 10. patients with either coagulation disorders or skin conditions (such as diseases, infections, ulcers, scars, or tumors at the acupuncture sites) that would preclude acupuncture; 11. strong needle phobia or unwillingness to receive acupuncture treatment; 12. any other condition (e.g., geographical remoteness, history of poor adherence) that, in the opinion of the investigator, would make the patient unsuitable for the study or likely to be non-compliant with the protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ulcerative colitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ulcerative colitis drugs put under the microscope for hidden clot risk
- Can a cheap Anti-Inflammatory drug calm ulcerative colitis?
- Which IBD therapy works best for kids? researchers compare two approaches
- Can trained peer mentors ease the mental toll of IBD?
- Can a new infusion drug calm ulcerative colitis?
- A breath test for gut disease? researchers hunt for invisible clues